May 1, 2010
House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD. JAMA. 2010 Apr 28;303(16):1603-9
This RCT examined compared a strategy of homocysteine reduction using folic acid, vitamin B6, and vitamin B12 versus placebo in patient with diabetic nephropathy. The active therapy arm experienced a greater decrease in GFR and an increase in vascular events.
![]()
May 1, 2010
NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. N Engl J Med. 2010 Apr 22;362(16):1477-90
9306 patients with IGTT and established cardiovascular disease or cardiovascular risk factors were randomized to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. After a median 5 year follow-up, there was a relative reduction of 14% in the incidence of diabetes in the valsartan group. [...]
![]()
March 23, 2010
NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. N Engl J Med. 2010 Apr 22;362(16):1477-90
This RCT randomized patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo in addition to lifestyle modification. No reduction in cardiovascular events was noted at 5 years, but the incidence of diabetes was reduced; 33.1% in the valsartan group vs 36.8% [...]
![]()
March 23, 2010
ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. N Engl J Med. 2010 Apr 29;362(17):1575-85
In the ACCORD BP study, patients with type 2 diabetes at high risk for cardiovascular events were randomized to a target systolic blood pressure of <120 mmHg vs <140 mmHg. After 4.7 years, there was no significant difference in cardiovascular events or mortality but there was an increase in serious adverse events related to anti-hypertensive [...]
![]()
March 1, 2009
Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P, VA NEPHRON-D Investigators. Clin J Am Soc Nephrol. 2009 Feb;4(2):361-8
March 1, 2009
Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T, Mitchell A, SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. J Am Soc Nephrol. 2009 Mar;20(3):655-64
September 1, 2008
McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. Am J Kidney Dis. 2008 Sep;52(3):454-63
May 1, 2008
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. N Engl J Med. 2008 Feb 7;358(6):580-91
February 1, 2008
Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Lancet. 2008 Jan 12;371(9607):117-25
Recent Comments